Breast Cancer Menubar
Breast Cancer
Breast Cancer
Treat hormone-sensitive breast cancer with
bioidentical PROGESTERONE
It's all about the receptors!
A large international breast cancer research team
(published in "Nature"),
made
the eye-opening discovery of how
receptors that mediate activity of the female sex hormones
(estrogen
and progesteronE)
interact with DNA to
control the growth of hormone-receptor positive breast cancers.
(Mohammed et al, 2015).
The American Cancer
Society estimates that 2 out of 3 breast cancer cases are hormone-receptor
positive.
•
Estrogen activates
estrogen receptors, which are agents that
turn on cancer-promoting genes in breast cancer.
•
PROGESTERONE activates
progesterone receptors, which bind to and
'reprogram'
estrogen receptors, transforming them into agents that turn on genes to slow down or reverse the
cancer cell growth.
The researchers emphasize that their conclusions ONLY apply to
natural, BIOIDENTICAL progesterone .
Premarin + Provera combination shown to increase risk of
breast cancer (also endometrial and ovarian cancers)
The Woman's Health Initiative (WHI)
study demonstrated that a combination of Premarin (conjugated
equine estrogens (CEEs, primary ingredients: sodium estrone sulfate and sodium equilin sulfate, which convert to
ESTRADIOL, then ESTRONE)
and
Provera (the
progestin Medroxyprogesterone
acetate (MPA), a synthetic progesteronE) produces a 26% increase in invasive breast cancer.
(Rossouw et al,
2002)
The risk of breast cancer was significantly greater
with HRT utilizing CEE's with Provera™)
(containing
the
progestin MPA)
than with HRT containing micronized progesterone. (Fournier
et al, 2005) or when utilizing a non-CEE estrogen
combined with a
progestin other than MPA
(de
Lignières et al
Synthetic
Sex Steroids
- "Frankinstein Forms
Since
estrogen dominance over progesterone is a common
problem today BIOIDENTICAL
PROGESTERONE
supplementation in hormone-sensitive breast cancers could indeed increase
survival rates.
Estrogen dominance treatment 1-2-3
How to supplement PROGESTERONE
The scientists in the "Nature" study reiterate the findings of Drs. Zava and
Lee in 2002:
Women with
estrogen dominance, where progesterone levels are low relative to
estrogen levels, are more likely
to get breast cancer and have poorer treatment outcomes. Drs Zava and
Lee and Virginia Hopkins, coauthors of
What Your Doctor May Not Tell You About™ Breast Cancer , concluded that
estrogen dominance causes
estrogen receptors to
activate genes such as Bcl-2 that are known to promote the rapid growth of
cancer cells.
When progesterone
is raised to healthy levels relative to
estrogen, it turns on genes that can
prevent breast cancer from occurring and reduce the size of existing tumors. Dr.
Lee and Dr. Zava cited research showing that
progesterone
References:
Mohammed, Hisham, et al (2015) Progesterone receptor modulates ER-a action in breast
cancer. Nature ; 523; 313-317. Link .
Perks, Bea (17 Jul 2015) Progesterone receptor could slow breast cancer growth.
Pharmaceutical Journal. LInk .
Rossouw JE,
Anderson GL,
Prentice RL,
LaCroix AZ,
Kooperberg C,
Stefanick ML,
Jackson RD,
Beresford SA,
Howard BV,
Johnson KC,
Kotchen JM,
Ockene J
(2002 Jul 17)
Writing Group
for the Women's Health Initiative Investigators.
Risks and benefits of estrogen plus progestin
in healthy postmenopausal women: principal results From the Women's Health
Initiative randomized controlled trial.
JAMA. 288(3):321-33
PubMed
de Lignières
B,
de Vathaire F,
Fournier S,
Urbinelli R,
Allaert F,
Le MG,
Kuttenn F.
(2002 Dec) Combined hormone
replacement therapy and risk of breast cancer in a French cohort study of 3175
women.
Climacteric. 5(4):332-40.
Researchgate
Fournier A,
Berrino F,
Riboli E,
Avenel V,
Clavel-Chapelon F.
(2005 Apr 10) Breast cancer
risk in relation to different types of hormone replacement therapy in the
E3N-EPIC cohort.
Int J Cancer. 114(3):448-54.
PubMed
